ClinicalTrials.gg
Active, not recruitingNCT06393504Updated Aug 19, 2025

Database Study to Provide Information on Pregnancy and Infant Outcomes Among Women Exposed to QUVIVIQ (Daridorexant)

An observational study in Insomnia Disorder, sponsored by Idorsia Pharmaceuticals Ltd.. Active, not recruiting at 1 site in United States. Open to female participants aged 15 Years to 50 Years. Per ClinicalTrials.gov, last updated 2025-08-19.

Sponsored by Idorsia Pharmaceuticals Ltd. · Observational

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Retrospective
Enrollment
2,095
Ages
15 Years to 50 Years
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-18

Among 11 studies in Sleep Initiation and Maintenance Disorders by Idorsia Pharmaceuticals Ltd. — none open to participants now, 1 under way, none of them phase 3. Sleep Initiation and Maintenance Disorders · Idorsia Pharmaceuticals Ltd..

Started
2023
with 1 other
Observational
2 of 11
none open now
Registered
10th of 11
by date

Among the 11 studies in Sleep Initiation and Maintenance Disorders by Idorsia Pharmaceuticals Ltd., this one is one of 2 that started in 2023, is one of 2 observational ones, and was the 10th registered.

Sleep Initiation and Maintenance Disorders

2,732 studies on the registry are indexed under Sleep Initiation and Maintenance Disorders; 733 are open to participants now.

Browse Sleep Initiation and Maintenance Disorders studies →

Open to participants now

None of the 11 studies in Sleep Initiation and Maintenance Disorders by Idorsia Pharmaceuticals Ltd. is open now. The open studies under Sleep Initiation and Maintenance Disorders, anywhere →

Who these studies take

Of the 392 Sleep Initiation and Maintenance Disorders studies recruiting now, 155 (40%) set no upper age limit and 207 (53%) stop at 75 or younger; 59 take children under 18; 110 take healthy volunteers.

This study: 15 Years to 50 Years · female · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 11 studies in Sleep Initiation and Maintenance Disorders by Idorsia Pharmaceuticals Ltd. as a file.
02

Study summary

Healthcare claims database study to provide safety information on maternal, fetal and infant outcomes among women exposed to QUVIVIQ (daridorexant) during pregnancy

Read the detailed description

This is a longitudinal observational cohort study using an electronic database of healthcare claims data. Safety information will be retrospectively collected from the database and pre-specified diagnostic codes will be used to identify pregnancy and infant outcomes. The study will include two phases, a patient accrual phase (Phase 1) and an analysis phase (Phase 2).

Descriptive statistics will be conducted to characterize the patient population and to support the interpretation of comparative analyses. Comparative analyses will be performed to estimate the effect of QUVIVIQ exposure during pregnancy on the study outcomes. Approximately 419 mother-infant pairs with exposure to QUVIVIQ and 1676 mother-infant pairs with exposure to non-orexin receptor antagonist insomnia medication are expected with a 1:4 ratio of exposed:active comparator patients.

Analysis of the prevalence of each specific pregnancy or infant outcome will comprise: (1) a comparison between women with insomnia exposed to QUVIVIQ during or shortly prior to pregnancy (QUVIVIQ-exposed group) and women with insomnia exposed to any non-orexin receptor antagonist insomnia medication during or shortly prior to pregnancy (active comparator group); (2) a comparison between women with insomnia exposed to QUVIVIQ during or shortly prior to pregnancy (QUVIVIQ-exposed group) and women with insomnia unexposed to any insomnia medication during or shortly prior to pregnancy (unexposed comparator group).

03

Conditions studied

  • Insomnia Disorder

Keywords

  • Pregnancy
04

Who can participate

Ages eligible
15 Years to 50 Years
Sexes eligible
Female
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Women with an end of pregnancy event between 1 May 2022 and 31 May 2027 (called the "intake period") and a diagnosis of insomnia disorder are included in the base cohort, from which the exposure- and outcome-specific analytic cohorts will be created.

Eligibility criteria

  1. Evidence of a singleton end of pregnancy event during the intake period.
  2. ≥ 1 insomnia diagnosis during the period which begins 12 months prior to the date of conception and ends at the end of pregnancy.
  3. Continuous medical and pharmacy insurance coverage during the period which begins 6 months prior to the date of conception and ends at the date of conception plus 40 weeks (equivalent to 42 gestational weeks).
  4. Age 15 to 50 years at the date of conception.
  5. No dispensing of known or suspected teratogenic medications during the period which begins 5 half lives of that medication prior to the date of conception and ends at the end of pregnancy.
  6. No exposure to other orexin receptor antagonists during the exposure period, i.e., suvorexant, lemborexant, and any orexin receptor antagonists newly approved during the intake period.
05

Study design

Observational model
Cohort
Time perspective
Retrospective
Enrollment
2,095 participants (estimated)
Patient registry
No

Groups and cohorts

  • QUVIVIQ-exposed group

    Pregnant women with insomnia exposed to QUVIVIQ during pregnancy or within 5 half-lives prior to date of conception.

    Drug: Daridorexant

  • Active comparator group

    Pregnant women with insomnia exposed to non-orexin receptor antagonist insomnia medications during pregnancy or within 5 half-lives of the respective insomnia medication prior to date of conception.

    Drug: Non-orexin receptor antagonist insomnia medication

  • Unexposed comparator group

    Pregnant women with insomnia unexposed to insomnia medications during pregnancy and within 5 half-lives of any insomnia medication taken prior to date of conception.

    Other: No insomnia medication

Interventions

  • Daridorexant received during or shortly prior to pregnancy.

    Also known as: QUVIVIQ

  • DrugNon-orexin receptor antagonist insomnia medication

    Non-orexin receptor antagonist insomnia medication received during or shortly prior to pregnancy.

  • OtherNo insomnia medication

    No insomnia medication received during or shortly prior to pregnancy.

06

What researchers measure

Primary outcomes

  1. Prevalence of major congenital malformations (MCMs)

    MCMs will be identified as pre-specified diagnostic codes for malformations included in the National Birth Defects Prevention Network's birth defects descriptions (identified through maternal and infant claims). MCMs with etiologies presumed not to be associated with drug exposure, such as chromosomal abnormalities, genetic syndromes, prematurity-related defects, and positional effects, will be excluded from the definition of MCMs.

    Time frame: From May 2022 to April 2028 (6 years)

Secondary outcomes

  1. Prevalence of spontaneous abortions (SABs)

    An SAB is defined as the loss of an embryo before 20 gestational weeks (identified through maternal claims).

    Time frame: From May 2022 to April 2028 (6 years)

  2. Prevalence of stillbirths (SBs)

    An SB is defined as the loss of a fetus at or after 20 gestational weeks (identified through maternal claims).

    Time frame: From May 2022 to April 2028 (6 years)

  3. Prevalence of small for gestational age infants (SGAs)

    SGA is defined as birth weight less than or equal to the tenth percentile for gestational age (identified through maternal and infant claims).

    Time frame: From May 2022 to April 2028 (6 years)

  4. Prevalence of preterm births (PTBs)

    PTB is defined as a live birth before 37 gestational weeks (identified through maternal and infant claims).

    Time frame: From May 2022 to April 2028 (6 years)

  5. Prevalence of induced abortions (IABs)

    An IAB is defined as the elective termination of the pregnancy (identified through maternal claims).

    Time frame: From May 2022 to April 2028 (6 years)

07

Study locations

1 site
  • Carelon Research
    Wilmington, Delaware 19801, United States
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Nov 2023 (actual). Primary completion is estimated for Apr 2028, 53 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 26, 2024
First posted
May 1, 2024
StartActual
Nov 30, 2023
Primary completionEst.
Apr 2028
CompletionEst.
Apr 2028
Last update
Aug 19, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 19, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06393504
Collaborators
Carelon Research
Responsible party
Sponsor
First posted
May 1, 2024
Start date
Nov 30, 2023
Primary completion
Apr 2028 (estimated)
Completion
Apr 2028 (estimated)
Last update
Aug 19, 2025

Study contacts

Clinical Trials Study Director
study director · Idorsia Pharmaceuticals Ltd.

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Apr 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion